Palmitoylethanolamide-based nutraceutical Calmux in preventive treatment of migraine
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 25 adults (22 women) with episodic migraine, with or without aura, at one Spanish centre
- Dose used in the study
- A palmitoylethanolamide-based product (Calmux) every 12 hours; amount per dose not in the abstract
- Duration
- 3 months
- What was measured
- Monthly headache days, days of painkiller use, pain intensity, HIT-6 and MIDAS impact scores, sleep quality
What the authors reported
Headache days fell from 10 to 6.6 a month, painkiller days from 9.2 to 4.1, and pain intensity from 8.1 to 5 out of 10 (all p < 0.005). No adverse events attributed to treatment.
Limits of this study
No control group, which the author states; 25 patients; single author and centre. Migraine has a large placebo response in open studies. The product's other ingredients, if any, are not described in the abstract.
Source
PubMed 35598579 · doi:10.1016/j.clineuro.2022.107282
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.